首页> 外文OA文献 >Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

【2h】

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

机译：白细胞介素-6受体抑制与巯基霉素可减少类风湿性关节炎的疾病活性，对疾病改性的抗胃部药物的反应不足：与传统疾病修饰的抗胃部药物治疗研究组合的Tocolizumab

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A. da Silva; Emma Alecock; Thasia Woodworth; Juan J. Gomez-Reino;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dru [J] . Genovese MC, McKay JD, Nasonov EL, Arthritis and Rheumatism . 2008,第10期

机译：用tocilizumab抑制白介素6受体会降低类风湿关节炎的疾病活动性，而对改变疾病的抗风湿药的反应不足：tocilizumab与传统的改变疾病的抗风湿性药物结合
2. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan- European TOCERRA register collaboration [J] . Lauper Kim, Nordstrom Dan C., Pavelka Karel, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第9期

机译：与TNF抑制剂与TNF抑制剂的比较有效性作为单药治疗或与常规的合成疾病改性抗逆素药物在使用至少一种生物学疾病改性的抗腹性药物后用类风湿性关节炎患者：从泛欧托拉登记协作分析
3. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) [J] . BurmesterG.R., Rubbert-RothA., CantagrelA., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第1期

机译：对中度至重度类风湿性关节炎患者皮下使用tocilizumab与静脉使用tocilizumab联合传统的改变病情的抗风湿药的安全性和有效性的随机，双盲，平行研究（SUMMACTA研究）
4. Extended report: A randomised double-blind parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) [O] . Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, -1

机译：扩展报告：对中度至重度类风湿关节炎患者皮下使用tocilizumab对比静脉使用tocilizumab联合传统的改变病情的抗风湿药的安全性和有效性的随机双盲平行研究（SUMMACTA研究）
5. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration [O] . Kim Lauper, Dan C Nordström, Karel Pavelka, 2018

机译：与TNF抑制剂与TNF抑制剂为单药治疗的比较效果或与常规合成疾病改性抗逆素药物在使用至少一种生物学疾病调制的抗耳动药物之后的类风湿性关节炎：从泛欧洲托尔拉注册协作分析

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

著录项

引文网络

相似文献

相关主题

期刊订阅